However, treatment with an RAS antagonist-based regimen, including an Ang II converting enzyme (ACE) inhibitor or ARB, prevented more cardiovascular events than did other regimens in diabetic patients with or without hypertension [30,31]. This evidence concerns the gene ACE and hypertensive disorder.